×
Sign in
Menu
Home
Resources
Back To Top
×
Contact the Presenter
×
Add To Cart
×
Test
ESMO Congress 2022
Final Programme PDF
Advanced Search
09.09.2022
10.09.2022
11.09.2022
12.09.2022
13.09.2022
Educational session
Industry Satellite Symposium
Multidisciplinary session
Opening session
Patient Advocacy session
Proffered Paper session
Special session
Special symposium
Young Oncologist session
10:00
11:00
12:00
13:00
14:00
15:00
16:00
17:00
18:00
19:00
20:00
4.A - Antibes Auditorium
14:00(1h 30m)
Are novel immunotherapeutics and targeted treatments going to transform the management of CRC?
4.B - Brest Auditorium
16:00(1h 30m)
Proffered Paper session: Breast cancer, metastatic
14:00(1h 30m)
Updates in the standard of care of metastatic breast cancer
6.P - Paris Auditorium
12:00(1h 45m)
Opening session
7.1.C - Cannes Auditorium
16:00(1h 30m)
Adjuvant and perioperative therapy for non-colorectal GI cancers: Latest status
14:00(1h 30m)
Using molecular data that impacts clinical practice
7.1.D - Dijon Auditorium
10:15(1h 30m)
Deciphera Pharmaceuticals - From clinical trial to clinical practice: novel strategies for treating patients with advanced GIST
16:00(1h 30m)
Emerging treatment strategies for non-metastatic NSCLC
14:00(1h 30m)
Exploiting synthetic lethality: The next generation
18:00(1h 30m)
Servier - Interpreting real-world data to better manage patients with metastatic colorectal cancer
7.2.E - Évry Auditorium
18:00(1h 30m)
Gilead and Kite Oncology - CAR T-cell therapy: The next frontier in immuno-oncology
10:15(1h 30m)
Mirati Therapeutics, Inc. - Advancing Tailored Therapies in NSCLC and KRASG12C-Driven Tumors
16:00(1h 30m)
Perioperative strategies in high-risk and oligometastatic renal cell (RCC) and urothelial cancers (UC)
7.2.F - Fécamp Auditorium
14:00(1h 30m)
Proffered Paper session: Gynaecological cancers
16:00(1h 15m)
Proffered Paper session: Investigational immunotherapy
7.3.G - Grenoble Auditorium
16:00(1h 30m)
New discoveries in cancer using single cell and spatial technologies
10:15(1h 30m)
Novartis - Guiding Through Oesophageal Cancer: Expert Insights on the Patient Journey From Diagnosis to Treatment
18:00(1h 30m)
PeerView Oncology - SERDs at the Inflection Point in Pretreated ER+/HER2- Breast Cancer: Addressing Unmet Needs, Establishing New Standards of Care, and Improving Patient Outcomes With Novel ER-Targeting Therapies
14:00(1h 30m)
Ultra-rare sarcoma: Navigating an endless sea
7.3.H - Honfleur Auditorium
18:00(1h 30m)
F. Hoffman-La Roche LTD - Navigating the possibilities of personalised healthcare in oncology
14:00(1h 30m)
How the tumour microenvironment affects outcome and therapy response?
10:15(1h 30m)
PeerView Oncology - Targeting HER2-Low Expression in Breast Cancer: Evaluating the Evidence, Challenges, and Opportunities for Expanding Treatment Benefit to More Patients
16:15(1h)
Plenty of choices in rectal cancer
7.3.M - Marseille Auditorium
16:00(1h 30m)
Patient Advocates and their expertise: How to get involved
14:00(1h 30m)
The impact of COVID-19 on patients with cancer: Lessons learnt and pathway for the future
7.3.O - Orléans Auditorium
14:00(1h 30m)
Advances in non-cutaneous melanoma
10:15(1h 30m)
Bristol Myers Squibb - GI Cancer and Immuno-Oncology Today: Best Practice and Clinical Challenges
16:00(1h 30m)
ESMO in collaboration with MASCC- Emerging toxicities to targeted therapies: Management strategies and future directions
18:00(1h 30m)
Janssen-Cilag International NV - Catching it early, getting it right: optimal disease and patient management from biomarkers to treatment selection for bladder cancer
7.3.Q - Quimper Auditorium
10:15(1h 30m)
ACE Oncology - Navigating Treatment Decisions in Advanced NSCLC: Update on Molecular Testing and New Targeted Treatment Options
18:00(1h 30m)
Merck - From complex to simple: The journey to strategic sequencing in the management of mCRC
14:00(1h 30m)
Proffered Paper session: CNS tumours
16:15(1h)
Special session: Ovarian cancer Consensus
7.3.T - Toulouse Auditorium
16:00(1h 30m)
Challenging the use of small cell lung cancer as a paradigm for extrapulmonary neuroendocrine carcinoma
14:00(1h 30m)
How diagnostic tools impact therapy of haematological malignancies
7.3.U - Urval Auditorium
14:00(1h 30m)
5-year impact of new registered indications on the ESMO-MCBS
15:45(1h 45m)
7th ESMO Designated Centres of Integrated Oncology and Palliative Care and Awards Session: Where are we going and what’s next
Networking Hub
17:30(1h)
ON-SITE ONLY: Young Oncologists Vesalius Talk
7.3.L - Lyon
14:00(1h 30m)
ON-SITE ONLY: Young Oncologist Mentorship sessions
×
Dialog
×
Sponsored Access
Access to the resources are offered to you by
ESMO Events